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Abstract Some children with steroid-sensitive nephrotic
syndrome (SSNS) have been reported to suffer relapses in
adulthood, but the clinical course of such adults is unclear.
Four children with SSNS suffered relapses after 30 years of
age. Those 4 patients developed frequently relapsing
nephrotic syndrome (NS) between 2 and 10 years of age.
They were treated with prednisolone (PSL) combined with
cyclophosphamide in 3 patients, mizoribine in 2, and
cyclosporine in 1 during childhood, and with cyclosporine
in 2 during adulthood. After 20 years of age, the frequency
of relapses gradually decreased. The last relapse occurred
between 33 and 39 years of age, and proteinuria disap-
peared within 1 month after the start of treatment with
PSL. At the last follow-up, all 4 patients continued to
receive PSL, had normal renal function, and were in
complete remission of NS when they were between 33 and
41 years of age. Although the long-term outcome of SSNS
is usually considered to be favorable, pediatricians should
be aware that some children with SSNS may require long-
term treatment during adulthood.
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Introduction
Long-term outcome of steroid-sensitive nephrotic syn-
drome (SSNS) is usually considered to be good. Relapses
of SSNS become less frequent towards puberty, and
eventually permanent remission is achieved. Recent reports
have shown that almost one-third of children with SSNS
suffer a relapse during adulthood [1, 2]. The clinical course
in adult patients with childhood-onset SSNS is unclear.
Case report
Four patients with childhood-onset SSNS had a relapse
after 30 years of age (Table 1). Nephrotic syndrome (NS)
was diagnosed in patients who had heavy proteinuria (more
than 40 mg/m2/h) and hypoalbuminemia (serum albumin
\2.5 g/dL). Patients who responded during 8 weeks of
prednisolone (PSL) treatment were defined as SSNS.
Relapse was defined as a reappearance of proteinuria (2?
or greater by dipstick for 3 consecutive days). Frequent
relapses were defined as two or more relapses within the
first 6 months after initial response or four or more relapses
during any 12-month period [3]. All four patients were
treated with PSL (60 mg/m2/day) until remission was
achieved. PSL was then tapered using alternate-day doses
over a six-week period. The first relapse was treated the
same as the initial treatment. The PSL was tapered more
slowly and the dose of PSL was determined individually
according to the threshold at which the relapse occurred.
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Estimated glomerular filtration rate was calculated by the
method of Matsuo et al. [4]. The standard deviation (SD) in
patient height was calculated using the mean Japanese
adult height of 170.8 ± 5.8 cm for males and 158.1 ±
5.3 cm for females.
Their ages at the onset of NS ranged between 2 and
10 years. Neither hypertension, hematuria, nor renal fail-
ure was noted in these 4 patients. Anti-nuclear antibody
was negative and serum IgA and complement levels were
normal. The number of relapses of NS was between 35
and 53, and frequently relapsing NS was noted in all
patients. Renal biopsy was not performed in cases 2–4.
They were treated with PSL combined with cyclophos-
phamide (CY) in 3 patients (cases 1–3), mizoribine (MZ)
in 2 (cases 1 and 2), and cyclosporine (CyA) in 3 (cases 1,
3, and 4). CY at a dose of 2 mg/kg for 8–12 weeks, MZ at
a dose of 100 mg/m2, and CyA at a dose to target the
trough level of 100 ng/mL were used. The total dose (mg/
kg) of CY was 430 in case 1, 275 in case 2, and 90 in case
3. A microemulsion formulation of CyA was used in case
1. Cases 3 and 4 were treated with CyA before the mi-
croemulsion formulation was developed. Relapse was
noted until 39 years old in case 1. PSL was tapered more
slowly in adulthood than in childhood. During adulthood,
CyA was used for 1–2 years in cases 1 and 4. After
20 years of age, the frequency of relapses gradually
decreased (Table 2). At the last relapse, proteinuria dis-
appeared promptly after the start of PSL (Table 3). Their
adult heights were between -1.6 and 0.7 SD. Case 1 was
obese (body mass index of 30) and was treated with
antihypertensive drugs. At the last follow-up, all 4 patients
continued to receive PSL, had normal renal function, and
were in complete remission from NS, when they were
between 33 and 41 years of age (Table 4). They were not
admitted for relapses during adulthood, except for 1
admission for the 33rd relapse of case 1. Three patients
(cases 1–3) were working full-time. Case 4 was a
housewife with two children. Case 2 also had 2 children.
Two of the patients (cases 1 and 3) were not married.
There were no signs nor symptoms of insufficiency frac-
ture, aseptic necrosis of femoral capital epiphyses, glucose
intolerance, cataract, or malignant diseases in any of the 4
patients.
Table 1 Profiles of 4 children with relapse of nephrotic syndrome
after 30 years of age
Case 1 Case 2 Case 3 Case 4
Sex Male Male Female Female
Age at onset 6 years 2 years 2 years 10 years
Number of
relapses
35 53 51 44
Frequent
relapser
? ? ? ?
Renal biopsy
finding
FSGS - - -










39 years 35 years 34 years 33 years
Age at last
follow-up
41 years 36 years 35 years 33 years
FSGS focal segmental glomerulosclerosis, CY cyclophosphamide, MZ
mizoribine, CyA cyclosporine
Table 2 Number of relapses per year in each decade of age
0–9 years 10–19 years 20–29 years 30–39 years
Case 1 1.7 1.8 0.9 0.2
Case 2 3.6 1.7 0.6 0.3
Case 3 1.4 2.3 1.1 1.0
Case 4 – 2.0 2.0 1.5
Table 3 Dose of prednisolone and response to treatment with pred-
nisolone at the onset of nephrotic syndrome and at last relapse











Case 1 45 mg/day
(46.9)
6 days 20 mg/day
(9.7)
10 days
Case 2 30 mg/day
(55.6)
8 days 40 mg/day
(22.7)
9 days
Case 3 30 mg/day
(51.7)
7 days 5 mg/day (3.6) \4 weeksb
Case 4 60 mg/day
(54.5)
9 days 45 mg/day
(30.4)
7 days
a Time from the start of treatment with prednisolone
b Proteinuria was not tested until 4 weeks after treatment with
prednisolone
Table 4 Clinical findings at last follow-up
Case 1 Case 2 Case 3 Case 4
Height (standard deviation) 0.7 -0.8 -1.6 -1.5
Body mass index (kg/m2) 30 24 19 22
Blood pressure (mmHg) 132/76 130/76 90/40 120/70
Antihypertensive agents ARB etc. – – –
Serum creatinine (mg/dL) 0.7 0.7 0.6 0.5
eGFR (mL/min/1.73 m2) 100 99 99 113
Proteinuria – – – –
Treatment
Prednisolone (mg/day) 2.5 15 2 10
Cyclosporine (mg/day) 200 – – –
ARB angiotensin-receptor blocker, eGFR estimated glomerular fil-
tration rate
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Case 1
CY was used at the age of 7 and 10 years, and MZ between
the age of 19 and 20 years. He had a 33rd relapse at the age
of 29 years, and renal biopsy showed focal segmental
glomerulosclerosis. His body mass index was over 30 and
his renal function remained normal. Proteinuria disap-
peared 1 week after treatment with PSL. Focal segmental
glomerulosclerosis associated with obesity was suspected
[5]. An angiotensin-converting enzyme inhibitor was added
after the complete remission of NS. At his 34th relapse at
34 years old, he went into complete remission within
2 weeks after the treatment with PSL, and PSL was tapered
for 3 years. At his 35th relapse at 39 years old, CyA was
started, and angiotensin-converting enzyme inhibitor was
changed to angiotensin-receptor blocker and calcium
channel blocker.
Case 2
He was treated with CY at 8 and 15 years of age and MZ
for 1 year at 13 years of age. He had 6 relapses between 20
and 29 years of age. He developed his 52nd relapse at
31 years of age and was treated with PSL for 8 months. His
daughter also developed SSNS [6]. At 35 years of age, his
53rd relapse occurred, and PSL was on a tapering dose at
the last follow-up.
Case 3
CY, followed by CyA for 1 year, was used for growth
impairment due to continuous treatment with PSL at
5–10 mg/day at 13 years of age [7]. Her adult height
reached -1.6 SD. After 30 years of age, 6 relapses
occurred when PSL was tapered to 1 mg/day. At her 51st
relapse in 34 years old, she was treated with PSL 5 mg/
day, and her proteinuria disappeared within 1 month. She
was on PSL 2 mg/day at the last follow-up.
Case 4
CyA was used between 24 and 25 years of age. She had 4
relapses during treatment with CyA, and CyA was dis-
continued at her first pregnancy. She had relapses during
pregnancy at 26 and 31 years of age and received PSL
treatment. She delivered a normal baby in 2 pregnancies
[8]. After her second delivery, PSL was withdrawn. Her
42nd to 44th relapses occurred between 32 and 33 years of
age, and PSL treatment was restarted.
Discussion
Relapses of SSNS become less frequent towards puberty,
and eventually permanent remission is achieved. Studies
from the 1980s reported that no more than 10 % of children
had additional relapses in adulthood. More recent reports
indicated a relapse rate after 18 years of age of between 27
and 42 % [1, 2]. Most patients who have relapsed during
adulthood developed NS at a young age and were frequent
relapsers during childhood [2, 9, 10]. Between 1972 and
2013, 148 patients were diagnosed with SSNS before
15 years of age at Toho University Omori Hospital and
Sakura Hospital. Of the 34 patients who were followed
after 20 years of age, 12 had at least one relapse after
20 years. The mean onset age for the 12 patients was
6.8 ± 3.6 (2.2–12.7) years, and 11 of them were frequent
relapsers. Of the 5 patients who relapsed after 20 years of
age and were followed after 30 years of age, 4 patients had
one or more relapses after 30 years. To our knowledge,
only a few patients who relapsed after 30 years of age have
been reported. Relapses in a 33-year-old patient and a
39-year-old patient were reported [9, 11]. Kyrieleis et al.
[12] reported 5 patients whose onsets of frequently
relapsing minimal change nephrotic syndrome (MCNS)
ranged between 1 and 3 years of age, and who had relapses
between 32 and 42 years of age. However, the clinical
courses of these patients in adulthood were not described.
Patients with adult-onset MCNS who have transient
hypertension and impaired renal function during the
nephrotic phase are not rare, and therapeutic response is
slower than in children. According to a report by the
International Study of Kidney Disease in Children,
85–90 % of children with NS achieved complete remission
within 4 weeks and 90–95 % within 8 weeks after the start
of steroid treatment. In adult patients with MCNS, response
to steroid treatment may take up to 15 weeks. In some
studies of adult patients given PSL, remission occurred in
50–60 % of patients after 8 weeks of treatment, and in
70–75 % after 16 weeks [13]. In the 4 patients presented
here, the time period from the start of treatment with PSL
to the induction of complete remission was similar to that
of childhood NS. Frequency of relapse decreased with age,
and renal function was normal after 30 years of age. The
prognosis was similar to the children with SSNS, despite
their prolonged course of NS. There does not seem to be
any proven way to predict the individual relapse courses of
patients with SSNS at onset [1]. Evaluating the number of
relapses during a long-term course, as shown in Table 2 of
this report, may predict the frequency of relapse during
adulthood in some patients.
Both increased duration and a higher dose of PSL
treatment leads to prolonged remission. The Cochrane
database of systematic reviews suggested that duration of
108 CEN Case Rep (2014) 3:106–109
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PSL therapy was more important than the dose of PSL. In
children with SSNS treated with PSL for 7 months, fre-
quency of relapse over the course of 2 years significantly
decreased compared with that for SSNS children treated
with PSL for 2 months [14]. At relapse in adult patients,
PSL should be continued for 7 months.
Case 1 presented here suffered a relapse at 39 years of
age, and a relapse in a 42-year-old patient has also been
reported [12]. Although the long-term outcome of SSNS is
usually considered to be favorable, the chronic course and
prolonged treatments involved affect the quality of life of
children and also that of their families. Prolonged steroid
treatment may cause short stature, obesity, and hyperten-
sion in adulthood [2]. Social performance and quality of
life seemed to be relatively good in the 4 patients reported
here. Pediatricians should be aware that some children with
SSNS may require long-term treatment even after they
have entered adulthood.
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